[1]石苗苗, 王玉, 杨泽玉, 等. 儿童肺炎支原体肺炎合并气道黏液栓的临床特点及危险因素分析[J]. 新疆医科大学学报, 2020, 43(9): 1213-1217.
[2]Zhou Y L, Hu M T, Ye B, et al. Early prediction of necrotizing pneumonia from Mycoplasma pneumoniae pneumonia with large pulmonary lesions in children[J]. Sci Rep, 2020, 10(1): 19061.
[3]方云,柏长青,牛文凯,等.肺炎支原体CARDS毒素致病机制和应用研究进展[J].国际呼吸杂志,2021,41(18):1424-1427.
[4]胡亚美, 江载芳. 诸福棠实用儿科学[M], 译.7版. 北京: 人民卫生出版社, 2002: 1204-1205.
[5]国家卫生计生委合理用药专家委员会儿童用药专业组. 中国儿童肺炎支原体感染实验室诊断规范和临床实践专家共识(2019年)[J]. 中华儿科杂志, 2020, 58(5): 366-373.
[6]中华人民共和国国家卫生健康委员会. 儿童肺炎支原体肺炎诊疗指南(2023年版)[J]. 国际流行病学传染病学杂志, 2023, 50(2): 79-85.
[7]俞珍惜, 刘秀云, 江载芳. 儿童重症肺炎支原体肺炎急性期的相关因素分析[J]. 实用儿科临床杂志, 2011, 26(4): 246-249.
[8]张晗, 尚云晓. 重症肺炎支原体肺炎早期识别[J]. 中国实用儿科杂志, 2015, 30(3): 176-179.
[9]国家卫生健康委员会人才交流服务中心儿科呼吸内镜诊疗技术专家组, 中国医师协会儿科医师分会内镜专业委员会, 中国医师协会内镜医师分会儿科呼吸内镜专业委员会, 等. 中国儿科可弯曲支气管镜术指南(2018年版)[J]. 中华实用儿科临床杂志, 2018, 33(13): 983-989.
[10]Kannan T R, Baseman J B. ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens[J]. Proc Natl Acad Sci U S A, 2006, 103(17): 6724-6729.
[11]孙红匣, 王冬梅, 王海燕, 等. CARDS TX致病机制的研究进展[J]. 包头医学院学报, 2019, 35(9): 116-120.
[12]胡杨, 刘春峰. 儿童肺炎支原体相关肺外并发症临床表现及发病机制[J]. 中国小儿急救医学, 2021, 28(1): 7-11.
[13]Su X L, You A A, Luo H D, et al. Community-acquired respiratory distress syndrome toxin: unique exotoxin for M. pneumoniae[J]. Front Microbiol, 2021, 12: 766591.
[14]Hardy R D, Coalson J J, Peters J, et al. Analysis of pulmonary inflammation and function in the mouse and baboon after exposure to Mycoplasma pneumoniae CARDS toxin[J]. PLoS One, 2009, 4(10): e7562.
[15]Maselli D J, Medina J L, Brooks E G, et al. The immunopathologic effects of Mycoplasma pneumoniae and community-acquired respiratory distress syndrome toxin. a primate model[J]. Am J Respir Cell Mol Biol, 2018, 58(2): 253-260.
[16]Kannan T R, Coalson J J, Cagle M, et al. Synthesis and distribution of CARDS toxin during Mycoplasma pneumoniae infection in a murine model[J]. J Infect Dis, 2011, 204(10): 1596-1604.
[17]Techasaensiri C, Tagliabue C, Cagle M, et al. Variation in colonization, ADP-ribosylating and vacuolating cytotoxin, and pulmonary disease severity among Mycoplasma pneumoniae strains[J]. Am J Respir Crit Care Med, 2010, 182(6): 797-804.
[18]李燕兵, 李仿敏, 黄海燕. 社区获得性呼吸窘迫综合征毒素检测的价值[J]. 深圳中西医结合杂志, 2019, 29(13): 76-77.
[19]Li G, Fan L P, Wang Y Q, et al. High co-expression of TNF-α and CARDS toxin is a good predictor for refractory Mycoplasma pneumoniae pneumonia[J]. Mol Med, 2019, 25(1): 38.
[20]曹囡囡, 黄莉, 焦琼杰, 等. 基于NLRP3/IL-1β、IL-18通路探讨CARDS Tx在儿童重症肺炎支原体肺炎中的作用[J]. 医学研究杂志, 2023, 52(1): 61-65.
[21]刘峰. 难治性肺炎支原体肺炎的预测因素[J]. 中华实用儿科临床杂志, 2021, 36(16): 1221-1225.
[22]刘建华, 刘金荣, 唐晓蕾, 等. 难治性肺炎支原体肺炎患儿遗留闭塞性支气管炎的预测因素分析[J]. 中华儿科杂志, 2023, 61(4): 317-321.
[23]杨硕, 刘新颖, 王慧哲, 等. 儿童重症肺炎支原体肺炎危险因素的Meta分析[J]. 中国全科医学, 2024, 27(14): 1750-1760.
[24]Shen F F, Dong C J, Zhang T Q, et al. Development of a nomogram for predicting refractory Mycoplasma pneumoniae pneumonia in children[J]. Front Pediatr, 2022, 10: 813614.
[25]郭靖, 刘亚楠, 郝明明, 等. 血清铁蛋白和乳酸脱氢酶在小儿难治性支原体肺炎外周血中的表达及与预后的相关性[J]. 中华实验和临床感染病杂志:电子版, 2020, 14(2): 133-137.
[26]贺艺璇, 张春峰, 吴润晖, 等. D-二聚体在肺炎支原体肺炎患儿病情及预后判断中的应用[J]. 中华实用儿科临床杂志, 2019, 34(22): 1702-1706.
[27]刘莉萍. 儿童重症支原体肺炎的临床特征及相关危险因素分析[D]. 合肥: 安徽医科大学, 2022.
[28]邹映雪. 肺炎支原体肺炎炎症指标异常的临床意义[J]. 中华实用儿科临床杂志, 2021, 36(16): 1209-1214.
[29]Medina J L, Brooks E G, Chaparro A, et al. Mycoplasma pneumoniae CARDS toxin elicits a functional IgE response in Balb/c mice[J]. PLoS One, 2017, 12(2): e0172447.
[30]Medina J L, Coalson J J, Brooks E G, et al. Mycoplasma pneumoniae CARDS toxin exacerbates ovalbumin-induced asthma-like inflammation in BALB/c mice[J]. PLoS One, 2014, 9(7): e102613.
[31]马香, 孙静, 韩玉玲, 等. 肺炎支原体肺炎儿童社区获得性呼吸窘迫综合征毒素水平测定的临床意义[J]. 中华实用儿科临床杂志, 2018, 33(22): 1703-1706.
[32]Yoshikawa E S E, Tamiya S, Inoue Y, et al. Vaccine using community-acquired respiratory distress syndrome toxin as an antigen against Mycoplasma pneumoniae in mice[J]. Biochem Biophys Res Commun, 2022, 594: 81-87.
|